These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1902997)

  • 1. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
    Morfini M; Mannucci PM; Longo G; Cinotti S; Messori A
    Thromb Res; 1991 Feb; 61(3):285-90. PubMed ID: 1902997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
    Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
    Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
    Smith KJ; Lusher JM; Cohen AR; Salzman P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Properties of factor VIII/von Willebrand factor in two highly-purified factor VIII concentrates, Hemofil M and Monoclate, using monoclonal antibodies].
    Tanaka I; Yoshioka A; Shima M; Fujiwara T; Terada S; Nakai H; Miyata S; Sawamoto Y; Kamisue S; Fukui H
    Rinsho Ketsueki; 1989 Jul; 30(7):951-7. PubMed ID: 2509762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.
    Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P
    Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates.
    Berntorp E; Nilsson IM
    Eur J Haematol; 1988 Mar; 40(3):205-14. PubMed ID: 3128452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.
    Björkman S; Carlsson M; Berntorp E; Stenberg P
    Clin Pharmacokinet; 1992 May; 22(5):385-95. PubMed ID: 1505144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations.
    Aronson DL; Chang P
    Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity.
    Messori A; Morfini M; Blomback M; Cinotti S; Longo G; Schimpf K; Schumacher K; Novakova-Banet A; Delvos U; Kjellman H
    Thromb Res; 1992 Mar; 65(6):699-708. PubMed ID: 1636162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation.
    Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J
    Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII.
    El-Ekiaby M; Goubran HA; Radosevich M; Abd-Allah A; El-Ekiaby A; Burnouf T
    Haemophilia; 2011 Sep; 17(5):e884-8. PubMed ID: 21371202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter.
    Morfini M
    Haemophilia; 2011 Nov; 17(6):846-8. PubMed ID: 22029760
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
    Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
    Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of pharmacokinetics of replacement factor VIII.
    Mannucci PM; Morfini M
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):8-10. PubMed ID: 2128856
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclate-P--hemofil-M study.
    Seremetis S
    Ann Hematol; 1994; 68 Suppl 3():S45-7. PubMed ID: 7910038
    [No Abstract]   [Full Text] [Related]  

  • 20. High-purity factor VIII concentrates produced without using monoclonal antibodies.
    Mannucci PM; Gringeri A; Cattaneo M
    Ric Clin Lab; 1990; 20(4):227-37. PubMed ID: 2127470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.